Challenges of designing trials for the primary prevention of stroke.
OBJECTIVE
Prevention of a first stroke is an important strategy to reduce morbidity and mortality associated with cerebrovascular disease. In this discussion, we review challenges to development of clinical trials for prevention of a first stroke. Summary of Review- We discuss prevention of first stroke in the context of clinical trial design in the ARRIVE trial and a primary prevention trial in development for the elderly.


CONCLUSIONS
Stroke is an important outcome in cerebrovascular disease trials in the elderly, but it may be trumped by coronary heart disease as a more common end point.
Gorelick
Philip B
PB
Center for Stroke Research, Department of Neurology and Rehabilitation, University of Illinois College of Medicine at Chicago, 912 S Wood Street, Room 855N, Chicago, IL 60612, USA. pgorelic@uic.edu
D000368:Aged; D000369:Aged, 80 and over; D001241:Aspirin / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000453:epidemiology; D006801:Humans; D055825:National Institute of Neurological Disorders and Stroke (U.S.); D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D020521:Stroke / Q000517:prevention & control*; D014481:United States
D010975:Platelet Aggregation Inhibitors; D001241:Aspirin